NRIX Stock Overview A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Nurix Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Nurix Therapeutics Historical stock prices Current Share Price US$18.64 52 Week High US$29.56 52 Week Low US$7.65 Beta 2.11 1 Month Change -15.69% 3 Month Change -15.62% 1 Year Change 80.62% 3 Year Change -37.13% 5 Year Change n/a Change since IPO -1.95%
Recent News & Updates
Nurix Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia Dec 19
Nurix Therapeutics, Inc. Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia At the 66Th American Society of Hematology Annual Meeting Dec 10
Nurix Therapeutics Announces Webcast to Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented At the American Society of Hematology Annual Meeting Dec 02
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia Nov 21
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 Nov 18
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25% Nov 07 See more updates
Nurix Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia Dec 19
Nurix Therapeutics, Inc. Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia At the 66Th American Society of Hematology Annual Meeting Dec 10
Nurix Therapeutics Announces Webcast to Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented At the American Society of Hematology Annual Meeting Dec 02
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia Nov 21
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 Nov 18
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25% Nov 07
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth Oct 31
Nurix Therapeutics, Inc. Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia Oct 19
Nurix Therapeutics, Inc. Appoints Anil Kapur to Its Board of Directors Oct 18
Nurix: An Attractive Early-Stage Biotech Play Oct 08
Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares Sep 07
Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data Sep 04
Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans Jul 15
Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case Jun 19
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress Jun 18
What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You May 29
Nurix Therapeutics, Inc. Appoints Paula G. O’Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer May 29
Nurix Therapeutics Announces Board Chair Transition May 23
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies Apr 15
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues Apr 14 Nurix Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 10
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies Apr 10
Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024 Mar 28
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial Mar 12
Price target decreased by 9.4% to US$24.09 Feb 21
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet Feb 20
Chief Financial Officer notifies of intention to sell stock Feb 19
New major risk - Revenue and earnings growth Feb 18
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 17
Nurix Therapeutics, Inc. Announces Publication in the Journal Science Identifying A New Class of Btk Mutations That Are Susceptible to Nx-2127, A Novel Btk and Ikzf1/3 Degrader Feb 02
Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now Jan 16
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation Dec 29
Chief Financial Officer notifies of intention to sell stock Dec 21
Nurix Therapeutics, Inc. Presents Positive Clinical Data from its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, Nx-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Dec 12
Nurix Therapeutics, Inc. Announces Partial Clinical Hold for Nx-2127 Phase 1 Trial Nov 03
New minor risk - Share price stability Oct 31
Consensus revenue estimates increase by 21% Oct 20
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues Oct 14
Third quarter 2023 earnings: EPS exceeds analyst expectations Oct 14
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher Oct 13
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation Sep 30
New minor risk - Shareholder dilution Jul 14
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Jul 14 Nurix Therapeutics, Inc. Plans to Initiate Two New Phase 1b Dose Expansion Cohorts in Ongoing Phase 1a/1b Clinical Trial of NX-2127 in Patients with Relapsed or Refractory B-Cell Malignancies
Consensus revenue estimates increase by 39% Apr 20
Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts Apr 18
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully Apr 15
First quarter 2023 earnings: EPS and revenues exceed analyst expectations Apr 14
Consensus revenue estimates decrease by 23%, EPS upgraded Feb 16
Price target decreased by 7.7% to US$31.45 Feb 13
Full year 2022 earnings: EPS and revenues miss analyst expectations Feb 10
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting Dec 15
We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate Nov 28
Price target decreased to US$34.91 Nov 16
Nurix Announces Initial Nx-1607 Phase 1 Data Presented At the 37Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc) Demonstrating Targeted Cbl-B Inhibition in Patients with Advanced Malignancies Nov 11
Nurix Therapeutics Inc. Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation Summit Oct 27
Price target decreased to US$34.91 Oct 14
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 07
Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M Oct 06
Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors Sep 15
Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer Aug 04
Price target decreased to US$38.20 Jul 11
Price target decreased to US$38.80 Jul 08 Nurix Therapeutics, Inc. has announced a Derivatives Offering in the amount of $54.996046 million. Jul 08
Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M Jul 07
Nurix Therapeutics, Inc. Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites Jul 01
FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S. Jun 30
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) dropped from Russell 2000 Growth Index Jun 26
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully Jun 21
Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs At the Annual Meeting of the American Society of Clinical Oncology (ASCO) Jun 04
Chief Financial Officer exercised options to buy US$621k worth of stock. Jun 02
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development May 27 Nurix Therapeutics, Inc. Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948
High number of new directors Apr 27
Nurix Therapeutics, Inc. Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting Apr 09
First quarter 2022 earnings: EPS and revenues miss analyst expectations Apr 08
Nurix Therapeutics, Inc Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors Apr 06
Nurix Therapeutics Receives Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Mar 30 Nurix Therapeutics, Inc. Announces Resignation of Jeffrey K. Tong as Class II Member of the Board and as a Member of the Board's Audit Committee and Compensation Committee Mar 10
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth Mar 07
Price target decreased to US$47.33 Feb 10
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Jan 30
Consensus forecasts updated Jan 29
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts Jan 12
Chief Scientific Officer notifies of intention to sell stock Jan 07
Nurix Therapeutics, Inc. Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of Nx-5948 Dec 13
Nurix: Advancing Targeted Protein Modulation Therapies Nov 21
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth Nov 21
Chief Scientific Officer notifies of intention to sell stock Oct 31 Shareholder Returns NRIX US Biotechs US Market 7D -6.7% -1.7% -1.1% 1Y 80.6% -5.0% 22.4%
See full shareholder returns
Return vs Market: NRIX exceeded the US Market which returned 23.7% over the past year.
Price Volatility Is NRIX's price volatile compared to industry and market? NRIX volatility NRIX Average Weekly Movement 8.1% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: NRIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NRIX's weekly volatility (8%) has been stable over the past year.
About the Company Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
Show more Nurix Therapeutics, Inc. Fundamentals Summary How do Nurix Therapeutics's earnings and revenue compare to its market cap? NRIX fundamental statistics Market cap US$1.35b Earnings (TTM ) -US$176.98m Revenue (TTM ) US$56.42m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NRIX income statement (TTM ) Revenue US$56.42m Cost of Revenue US$204.12m Gross Profit -US$147.70m Other Expenses US$29.28m Earnings -US$176.98m
Last Reported Earnings
Aug 31, 2024
Earnings per share (EPS) -2.50 Gross Margin -261.76% Net Profit Margin -313.65% Debt/Equity Ratio 0%
How did NRIX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 04:07 End of Day Share Price 2024/12/30 00:00 Earnings 2024/08/31 Annual Earnings 2023/11/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Nurix Therapeutics, Inc. is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Joel Beatty Baird Peter Lawson Barclays
Show 19 more analysts 
